Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

Patrícia Pacheco, Nuno Marques, Paulo Rodrigues, Kamal Mansinho, Fernando Maltez, Nuno Janeiro, Cláudia Franco, Diva Trigo, Joana Batista, Luís Duque, Maria João Lopes, Maria João Aleixo, Ana Rita Silva, Raquel Tavares, João Alves, Susana Peres, Diana Póvoas, Sara Lino, Perpétua Gomes, Vânia AraújoCristina Lopes

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science